Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Juvisy sur Orge, France Clinical Trials

A listing of Juvisy sur Orge, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (59) clinical trials

A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma

Primary Objective: To evaluate the safety and tolerability of every 12 hours (q12h) and every 24 hours (q24h) administration of subcutaneous (SC) blinatumomab Secondary Objectives: To determine pharmacokinetics (PK) with continuous intravenous (cIV) and SC administrations To estimate the maximum tolerated dose (MTD) tested for blinatumomab administered subcutaneously To determine ...

Phase

7.8 miles

Learn More »

Characterize the safety, tolerability, ECG effects, pharmacokinetics and immunogenicity of anetumab ravtansine given as single agent and after inhibition of CYP3A4 and P-gp by concomitant administration of itraconazole in subjects with mesothelin-expressing advanced solid cancers

Phase

7.8 miles

Learn More »

- This is the first study where BAY1163877 is given to humans. Impact of the study is to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme ...

Phase

7.8 miles

Learn More »

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas

The primary objective of this study is to determine the recommended dose of ibrutinib when administered in combination with R-DHAP (rituximab + dexamethasone + cytarabine + cisplatin) or with R-DHAOx (rituximab + dexamethasone + cytarabine + oxaliplatin) in patients with relapsed or refractory B-cell malignancies eligible for autologous stem cell ...

Phase

7.8 miles

Learn More »

Multicenter Safety Trial Assessing an Innovative Tumor Molecular and Cellular Print Medical Device in Glioma

Diagnostic in cancerology keeps based on biopsy or exeresis tissues anatomopathologic analysis. Micro-invasive biopsy approaches reduces chirurgical aggressivity but also tissue amount The innovative Medical Device ProTool offers a micro-invasive biopsy approach in parallel with classical chirurgical proceeding. It allows to complete heterogeneity tumoral analysis and peri-tumoral tissue environment.

Phase

7.8 miles

Learn More »

SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias

Cerebellar ataxias (CA) and spastic paraplegias (SP) are genetically and clinically very heterogeneous. More than 40 loci are already known but the number of phenotypes is even greater suggesting further genetic heterogeneity. These progressive disorders are often severe and fatal, due to the absence of specific therapy. The SPATAX network ...

Phase

9.62 miles

Learn More »

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Patients with different types of dementia will be recruited and evaluated in national hospital departments for their usual neurological follow-ups. A blood sample will be proposed in the field of this research project, and the biological material will be stored at the DNA and Cell Bank of Institut de Fédératif ...

Phase

9.62 miles

Learn More »

Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

The CL1-64315-001 study is a phase I, international, multicentre, open-label, non-randomised, non-comparative study. This study is designed in two parts: one part for dose escalation, one part for dose expansion.

Phase

9.83 miles

Learn More »

A Study of Orally Administered JNJ-56136379 to Evaluate Safety Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I) and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)

Part 1: This is a first-in-human (FIH), double-blind (neither the researchers nor the participants know what treatment the participant is receiving), randomized (study medication assigned to participants by chance), placebo-controlled (an inactive substance; a pretend treatment [with no drug in it] that is compared in a clinical trial with a ...

Phase

9.88 miles

Learn More »